RESULTS: A total of 190 patients [average age 67.0±12.7 years old; 136 (71.6%) male; 134 (70.5%) Chinese, 48 (25.3%) Malay, 6 (3.2%) Indian and 2 (1.1%) other races] were analysed. Forty-six (24.2%) patients were on antiplatelets as compared to 144 (75.8%) patients who were not. Of these 46 patients, 39 (84.8%) patients had their antiplatelets stopped prior. Patients who were on antiplatelets prior to TTNA were older, more males and had more cardiovascular conditions as expected. Bleeding parameters including platelet level and coagulation profile were similar between the 2 groups. Based on the adjusted Logistics Regression model, chronic kidney disease is the only risk factor identified to have an increased risk of bleeding complications (adjusted OR 21.6, CI 1.5-320.7, p=0.03). 15.2% (7/46) of patients on antiplatelet therapy had bleeding complications, such as minor pulmonary haemorrhage, minor hemoptysis and hemothorax, compared to 10.4% (15/144) of patients without antiplatelet therapy, which was not statistically significant [OR 1.5, 95% CI (0.6 - 4.1), p=0.38). None of the patients whom antiplatelets were stopped had any complications from cessation of antiplatelets such as acute myocardial infarct or cerebrovascular events.